Neuronal signaling in schistosomes: current status and prospects for postgenomicsThe present review is one of a series of occasional review articles that have been invited by the Editors and will feature the broad range of disciplines and expertise represented in our Editorial Advisory Board.

Parasitic platyhelminths of the genus Schistosoma Weinland, 1858 (Trematoda, Digenea) are the etiological agents of human schistosomiasis, one of the most prevalent and debilitating parasitic diseases worldwide. Praziquantel is the only drug treatment available in most parts of the world and the effectiveness of the drug is threatened by the prospect of drug resistance. There is a pressing need to learn more about the basic biology of this organism and to identify molecular targets for new therapeutic drugs. The nervous system of schistosomes coordinates many activities that are essential for parasite survival, and as such is an attractive target for chemotherapeutic intervention. Until recently, very little was known about the molecular mechanisms of neuronal signaling in these organisms, but this is rapidly changing following the completion of the genome sequence and several recent developments in schistosome transgenesis and gene silencing. Here we review the current status of schistosome neurobiology and discuss prospects for future research as the field moves into a postgenomics era. One of the themes that will emerge from this discussion is that schistosomes have a rich diversity of neurotransmitters and receptors, indicating a more sophisticated system of neuronal communication than might be expected of a parasitic flatworm. Moreover, many of these transmitter receptors share little sequence homology with those of the human host, making them ideally suited for selective drug targeting. Strategies for characterization of these important parasite proteins will be discussed.